Citations

Clear

16280 citation(s) found for "Yu, David".

Faculty Opinions recommendation of Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.8008956.8388054 Get It

Faculty Opinions recommendation of Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.8769956.9293054 Get It

Faculty Opinions recommendation of Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.9814957.10517055 Get It

Faculty Opinions recommendation of Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.10062956.10815054 Get It

Faculty Opinions recommendation of Protective role of aerodigestive reflexes against aspiration: study on subjects with impaired and preserved reflexes.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.11406959.12428056 Get It

Faculty Opinions recommendation of High-resolution manometry studies are frequently imperfect but usually still interpretable.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13129957.14456055 Get It

Faculty Opinions recommendation of Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13340021.14707146 Get It

Faculty Opinions recommendation of Factors that predict relief from upper abdominal pain after cholecystectomy.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.11789958.14707145 Get It

Faculty Opinions recommendation of Novel probe-based confocal laser endomicroscopy criteria and interobserver agreement for the detection of dysplasia in Barrett's esophagus.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13381981.14750170 Get It

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
Anglesio, Michael S. , Kommoss, Stefan , Tolcher, Mary Catherine , Clarke, Blaise , Galletta, Laura, Porter, Henry, Damaraju, Sambasivarao , Fereday, Sián , Winterhoff, Boris , Yang, Winnie , Steed, Helen , Allo, Ghassan , Ferguson, Sarah E. , Teoman, Attila, García, Joaquín J. , Schoolmeester, John K., Tinker, Anna V. , Bowtell, David D.L. , Huntsman, David G. , Gilks, C. Blake, Kalloger, Steve E. , Senz, Janine , Shaw, Patricia H. , Bakkum‐Gamez, Jamie N. , McAlpine, Jessica N. , Anglesio, Michael S , Bowtell, David D , Fereday, Sian , Steed, Helen

Mayo Clinic

The Journal of Pathology | August 16, 2012 | Volume: 229 | Issue: 1 | Pages: 111-120

10.1002/path.4088 | PMID 22899400 Get It

AbstractMucinous ovarian carcinomas (MCs) typically do not respond to current conventional therapy. We have previously demonstrated amplification of HER2 in 6 of 33 (18.2%) mucinous ovarian carcinomas (MCs) and presented anecdotal evidence of response with HER2‐targeted treatment in a small series of women with recurrent HER2‐amplified (HER2+) MC. Here, we explore HER2 amplification and KRAS mutation status in an independent cohort of 189 MCs and 199 mucinous borderline ovarian tumours (MBOTs) and their association to clinicopathological features. HER2 status was assessed by immunohistochemistry (IHC), FISH, and CISH, and interpreted per ASCO/CAP guidelines, with intratumoural heterogeneity assessment on full sections, where available. KRAS mutation testing was performed with Sanger sequencing. Stage and grade were associated with recurrence on both univariate and multivariate analysis (p < 0.001). Assessment of HER2 status revealed overexpression/amplification of HER2 in 29/154 (18.8%) MCs and 11/176 (6.2%) MBOTs. There was excellent agreement between IHC, FISH, and CISH assessment of HER2 status (perfect concordance of HER2 0 or 1+ IHC with non‐amplified status, and 3+ IHC with amplified status). KRAS mutations were seen in 31/71 (43.6%) MCs and 26/33 (78.8%) MBOTs, and were near mutually exclusive of HER2 amplification. In the 189 MC cases, a total of 54 recurrences and 59 deaths (53 of progressive disease) were observed. Within MCs, either HER2 amplification/overexpression or KRAS mutation was associated with decreased likelihood of disease recurrence (p = 0.019) or death (p = 0.0041) when compared to cases with neither feature. Intratumoural heterogeneity was noted in 26% of HER2‐overexpressing cases. These data support the stratification of MCs for the testing of new treatments, with HER2‐targeted therapy as a viable option for HER2+ advanced or recurrent disease. Further research is required to delineate the molecular and clinical features of the ∼34% of MC cases with neither HER2 amplification nor KRAS mutations.